Sugi Predict

Sugi Predict / Compounds / SCHEMBL1740093

SCHEMBL1740093

SCHEMBL1740093

COc1ccc(CN(C(=O)OCC2c3ccccc3-c3ccccc32)[C@H](C(=O)O)C(C)C)c(OC(=O)OCC2c3ccccc3-c3ccccc32)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FABP5 Q01469 1/20 0.38
▸ ALDH1A1 P00352 5/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ LMNA P02545 3/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ HTT P42858 1/20 0.36
▸ KMT2A Q03164 4/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ MDM2 Q00987 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ POLB P06746 2/20 0.35
▸ HSD17B10 Q99714 1/20 0.34
▸ PIK3CG P48736 1/20 0.34
▸ TAS1R3 Q7RTX0 1/20 0.33
▸ TAS1R1 Q7RTX1 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ CASP3 P42574 1/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ SLC6A4 P31645 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29400602 0.91 FABP5 (0.39) FABP5ALDH1A1KDM4ELMNAL3MBTL1
SCHEMBL1738448 0.89 ALDH1A1 (0.34) FABP5ALDH1A1KDM4ELMNAL3MBTL1
SCHEMBL1739364 0.88 ALDH1A1 (0.38) FABP5ALDH1A1KDM4ELMNAL3MBTL1
SCHEMBL1737775 0.87 ALDH1A1 (0.38) FABP5ALDH1A1KDM4ELMNAL3MBTL1
SCHEMBL1740136 0.84 ALDH1A1 (0.35) FABP5ALDH1A1KDM4ELMNAL3MBTL1
SCHEMBL29398220 0.84 ALDH1A1 (0.44) FABP5ALDH1A1KDM4ELMNAL3MBTL1
SCHEMBL1740574 0.81 ALDH1A1 (0.34) FABP5ALDH1A1KDM4ELMNAL3MBTL1
SCHEMBL1738800 0.78 KMT2A (0.38) ALDH1A1KDM4ELMNASMN1; SMN2KMT2A
SCHEMBL1738792 0.76 ALDH1A1 (0.37) FABP5ALDH1A1KDM4ELMNAL3MBTL1
SCHEMBL31287230 0.76 KMT2A (0.43) FABP5ALDH1A1LMNAL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113754753-B Synthetic method of somalupeptide 深圳翰宇药业股份有限公司 2024-09-03 — — CN claimed
US-20250276995-A1 PRODUCTION METHOD FOR PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-04 — — US disclosed
EP-4522220-A1 PRODRUGS OF GLP-1 POLYPEPTIDE AND USES THEREOF Novo Nordisk A/S (DK) 2025-03-19 — — EP disclosed
WO-2025043696-A1 ANTIVIRAL POLYPEPTIDE ANALOGUE 上海多米瑞生物技术有限公司 2025-03-06 — — WO disclosed
EP-4499667-A1 MACROCYCLIC IMMUNOMODULATORS Bristol-Myers Squibb Company (US) 2025-02-05 — — EP disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 — — EP disclosed
WO-2024164864-A1 POLYPEPTIDE AND USE THEREOF 湖南九典制药股份有限公司 2024-08-15 — — WO disclosed
US-20240124517-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-04-18 — — US disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 — — US disclosed
WO-2023217744-A1 PRODRUGS OF GLP-1 POLYPEPTIDE AND USES THEREOF NOVO NORDISK A/S (DK) 2023-11-16 — — WO disclosed
US-20130338085-A1 MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE BIOMARCK PHARMACEUTICALS, LTD. 2013-12-19 — — US disclosed
US-8492518-B2 Mucin hypersecretion inhibitors and methods of use BIOMARCK PHARMACEUTICALS LTD. (US) 2013-07-23 — — US disclosed
US-8293870-B2 Mucin hypersecretion inhibitors and methods of use BIOMARCK PHARMACEUTICALS LTD (US) 2012-10-23 — — US disclosed
EP-2399599-A2 MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE Biomarck Pharmaceuticals, Ltd. (US) 2011-12-28 — — EP disclosed
US-20100197607-A1 MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE WILLIAMS, MASON L. 2010-08-05 — — US disclosed
US-20090275520-A1 MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE WILLIAMS, MASON L. 2009-11-05 — — US disclosed
US-7524926-B2 Mucin hypersecretion inhibitors and methods of use BIOMARCK PHARMACEUTICALS, LTD. (US) 2009-04-28 — — US disclosed
EP-1858538-A2 MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USE Biomarck Pharmaceuticals, Ltd. (US) 2007-11-28 — — EP disclosed
US-20060205664-A1 Mucin hypersecretion inhibitors and methods of use WILLIAMS, MASON L. 2006-09-14 — — US disclosed
WO-2006078899-A2 MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USE BIOMARCK PHARMACEUTICALS, LTD. (US) 2006-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124517-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE VIP, NPEPPS, ANPEP FABP5 2937/4885ALDH1A1 4655/4885KDM4E 3440/4885
US-20250276995-A1 PRODUCTION METHOD FOR PEPTIDE COMPOUND VIP, IAPP, QPCT FABP5 1731/4885ALDH1A1 4644/4885KDM4E 3685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback